Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective, randomized, subject/evaluator-masked post market clinical study at up to 2 sites at Gemini eye clinic in Czech Republic. Randomization will be done by the eye surgeon. The purpose of this post market clinical trial is to compare the safety and efficacy of Ophtesis Bio 3% with a similar 3% sodium hyaluronate OVD in routine cataract surgery.
The purpose of this clinical study is to evaluate the performance of the Ophtesis Bio 3%. The primary endpoint is the rate of intraocular pressure (IOP) spikes of 30 mmHG or greater at the 7-day postoperative visit. The secondary endpoint will be the rate of user acceptance evaluated using the surgeon questionnaire at the surgery day visit. Other key endpoints will include IOP and IOP change from baseline at the 7-day postoperative visit, rate of inflammation measured using Slip Lamp at the 7-day postoperative visit, and rates of serious and/or device-related adverse events. Number of Subjects/eyes: Up to 296 eyes will be enrolled to achieve approximately 148 operated eyes per group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study Product: Ophtesis Bio 3% | Subjects to receive Ophtesis Bio 3% in one eye |
| |
| Control Product: Healon Endocoat 3% | Subjects to receive Healon Endocoat 3% in one eye |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ophtesis Bio 3% ophthalmic viscosurgical device | Device | Intraocular surgery of the anterior segment, including cataract extraction and intraocular lens (IOL) implantation. The viscoelastic properties of OphtesisBio 3.0% allow lubrication, support and protection of ocular tissues during ophthalmic surgery. Maintains the depth of the anterior chamber during surgery, allows for efficient manipulation with reduced trauma to the corneal endothelium and other surrounding tissues. |
| Measure | Description | Time Frame |
|---|---|---|
| Intraocular pressure (IOP) | Rate of intraocular pressure (IOP) spikes of 30 mmHG or greater | 7 days |
| Surgeon questionnaire | The rate of user acceptance ten questions that can be answered on a scale from 1 to 5, 1 means the worst, 5 the best | first day |
| Measure | Description | Time Frame |
|---|---|---|
| Biomicroscopic Slit-Lamp Exam | Rate of inflammation | Pre-operative visit, 7 days |
| IOP change | IOP change from Pre-operative visit at the 7-day postoperative visit |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with cataract for which extraction and posterior intraocular lens (IOL) implantation have been planned for one or both eyes
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Martin Slovak, PhD | Contact | +420 730 873 183 | martin.slovak@gemini.cz | |
| Simona Rakusanova, Ing. | Contact | +420 730 873 184 | simona.rakusanova@gemini.cz |
| Name | Affiliation | Role |
|---|---|---|
| Pavel Stodulka, MD | Gemini Eye Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gemini Eye Clinic | Recruiting | Průhonice | 252 43 | Czechia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Healon Endocoat 3% ophthalmic viscosurgical device | Device | Healon@ EndoCoat OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including:
Healon@ EndoCoat maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation. |
|
| 7 days |
| IOP change | IOP change from Pre-operative to up to 1 hour post op | first day |
| Dilated fundus exam | Examination to help assess ocular health | Pre-operative visit, after only if medically indicated |
| Serious and /or Device-Related Adverse Events | Rates of serious and/or device-related adverse events | first day, 7 days |
| Gemini Eye Clinic | Completed | Vyškov | 682 01 | Czechia |
| Gemini Eye Clinic | Recruiting | Zlín | 76001 | Czechia |
|
| ID | Term |
|---|---|
| D002386 | Cataract |
| ID | Term |
|---|---|
| D007905 | Lens Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided